Cargando…

ABL2 suppresses FLT3-ITD-induced cell proliferation through negative regulation of AKT signaling

The type III receptor tyrosine kinase FLT3 is one of the most commonly mutated oncogenes in acute myeloid leukemia (AML). Inhibition of mutated FLT3 in combination with chemotherapy has displayed promising results in clinical trials. However, one of the major obstacles in targeting FLT3 is the devel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kazi, Julhash U., Rupar, Kaja, Marhäll, Alissa, Moharram, Sausan A., Khanum, Fatima, Shah, Kinjal, Gazi, Mohiuddin, Nagaraj, Sachin Raj M., Sun, Jianmin, Chougule, Rohit A., Rönnstrand, Lars
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355336/ https://www.ncbi.nlm.nih.gov/pubmed/28086240 http://dx.doi.org/10.18632/oncotarget.14577

Ejemplares similares

Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD
por: Kazi, Julhash U., et al.
Publicado: (2017)

The Src family kinase LCK cooperates with oncogenic FLT3/ITD in cellular transformation
por: Marhäll, Alissa, et al.
Publicado: (2017)

FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia
por: Chougule, Rohit A., et al.
Publicado: (2016)

Expression of GADS enhances FLT3-induced mitogenic signaling
por: Chougule, Rohit A., et al.
Publicado: (2016)

SRC-like adaptor protein 2 (SLAP2) is a negative regulator of KIT-D816V-mediated oncogenic transformation
por: Rupar, Kaja, et al.
Publicado: (2018)

Src-like adaptor protein 2 (SLAP2) binds to and inhibits FLT3 signaling
por: Moharram, Sausan A., et al.
Publicado: (2016)

The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
por: Moharram, Sausan A., et al.
Publicado: (2019)

Correction: The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
por: Moharram, Sausan A., et al.
Publicado: (2019)

Understanding the Role of Activation Loop Mutants in Drug Efficacy for FLT3-ITD
por: Kazi, Julhash U., et al.
Publicado: (2023)

Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation
por: Chougule, Rohit A., et al.
Publicado: (2019)

T-cell Acute Lymphoblastic Leukemia Cells Display Activation of Different Survival Pathways
por: Moharram, Sausan A., et al.
Publicado: (2017)

Acute leukemia cells resistant to PI3K/mTOR inhibition display upregulation of P2RY14 expression
por: Shah, Kinjal, et al.
Publicado: (2018)

Src-Like Adaptor Protein (SLAP) Binds to the Receptor Tyrosine Kinase Flt3 and Modulates Receptor Stability and Downstream Signaling
por: Kazi, Julhash U., et al.
Publicado: (2012)

Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation
por: Marhäll, Alissa, et al.
Publicado: (2018)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)

Arsenic trioxide induces autophagic degradation of the FLT3-ITD mutated protein in FLT3-ITD acute myeloid leukemia cells
por: Liu, Xiao-Jian, et al.
Publicado: (2020)

T cell receptor (TCR) signaling in health and disease
por: Shah, Kinjal, et al.
Publicado: (2021)

RUNX1 cooperates with FLT3-ITD to induce leukemia
por: Behrens, Kira, et al.
Publicado: (2017)

P479: TREATMENT IS SHAPING CLONAL EVOLUTION AND RESISTANCE PATTERNS IN MURINE KMT2A-REARRANGED LEUKEMIA WITH SUBCLONAL FLT3N676K
por: Falqués-Costa, Ton, et al.
Publicado: (2023)

Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
por: Iannotta, R., et al.
Publicado: (2022)

The GSK3β/Mcl-1 axis is regulated by both FLT3-ITD and Axl and determines the apoptosis induction abilities of FLT3-ITD inhibitors
por: Qiu, Yang, et al.
Publicado: (2023)

How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia
por: Haage, Tobias R., et al.
Publicado: (2023)

Phosphorylation-Dependent Regulation of WNT/Beta-Catenin Signaling
por: Shah, Kinjal, et al.
Publicado: (2022)

Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3
por: Nagai, Kozo, et al.
Publicado: (2018)

Wild‐type FLT3 and FLT3 ITD exhibit similar ligand‐induced internalization characteristics
por: Kellner, Fabienne, et al.
Publicado: (2020)

Overcoming AC220 resistance of FLT3-ITD by SAR302503
por: Kesarwani, M, et al.
Publicado: (2013)

Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia
por: Burchert, Andreas
Publicado: (2021)

MicroRNA networks in FLT3-ITD acute myeloid leukemia
por: Hoang, Dinh Hoa, et al.
Publicado: (2022)

Lack of FLT3-ITD in Tunisian childhood acute lymphoblastic leukemia
por: Frikha, Rim, et al.
Publicado: (2022)

FLT3-ITD Mutation and Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Case Study
por: Saeed, Shahzeb, et al.
Publicado: (2023)

A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia
por: Lee, Lauren Y., et al.
Publicado: (2021)

FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML
por: Kivioja, Jarno, et al.
Publicado: (2021)

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
por: Xu, Dan, et al.
Publicado: (2022)

The Aurora kinase/β-catenin axis contributes to dexamethasone resistance in leukemia
por: Shah, Kinjal, et al.
Publicado: (2021)

FLT3/ITD associated with an immature immunophenotype in PML-RARα leukemia
por: Takenokuchi, Mariko, et al.
Publicado: (2012)

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia
por: Pillinger, Genevra, et al.
Publicado: (2015)

Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML
por: Vachhani, Pankit, et al.
Publicado: (2016)

DOCK2: A novel FLT3/ITD leukemia drug target
por: Wu, Min, et al.
Publicado: (2017)

Feature genes predicting the FLT3/ITD mutation in acute myeloid leukemia
por: LI, CHENGLONG, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_j2hglsbsq167hcatqninkpmj50